Syncope Evaluation in Adults

Quick Reference

Critical Alerts

RED FLAGS - Immediate Risk Stratification Required:

• Syncope during exertion or while supine: Arrhythmic or structural cardiac cause until proven otherwise
• New cardiac symptoms: Chest pain, dyspnea, or palpitations preceding syncope
• Abnormal ECG findings: Bundle branch block, long/short QT, Brugada pattern, pre-excitation, pathological Q waves
• Family history of sudden cardiac death less than 40 years: Inherited arrhythmic syndromes
• Known structural heart disease: High risk of cardiac syncope
• ECG mandatory for ALL patients: Diagnostic yield 5-11% for identifying cause [1,2]
• Orthostatic vital signs essential: Present in 24% of elderly, 12% overall [3]

High-Risk Features Requiring Admission

Risk Stratification Tools

Canadian Syncope Risk Score (CSRS) [4,5]:

Risk Interpretation:

• Score -2 to 0: Very low risk (0.4% serious outcome at 30 days)
• Score 1-3: Low risk (3.6%)
• Score 4-5: Medium risk (12.9%)
• Score ≥6: High risk (28.9%)
• Score ≥1: Consider admission or intensive investigation [4]

San Francisco Syncope Rule (SFSR) [6]: Admit if ANY present (CHESS):

• C: Congestive heart failure history
• H: Hematocrit less than 30%
• E: ECG abnormality (any non-sinus rhythm or new changes)
• S: Shortness of breath
• S: Systolic BP less than 90 mmHg at triage

Sensitivity 98%, Specificity 56% for 7-day serious outcomes [6]

Emergency Diagnostic Priorities

---

Definition and Classification

Precise Definition

Syncope is a transient loss of consciousness (TLOC) due to global cerebral hypoperfusion, characterized by:

1. Rapid onset (seconds)
2. Short duration (typically less than 20 seconds, rarely > 2 minutes)
3. Spontaneous, complete recovery without intervention [1,2]

Key Pathophysiologic Threshold:

• Cerebral blood flow reduction to less than 50% of baseline for 6-8 seconds → loss of consciousness
• Mean arterial pressure less than 60 mmHg → inadequate cerebral perfusion in most individuals
• Return to horizontal position → restoration of cerebral blood flow → recovery [9]

Classification by Mechanism

The 2018 ESC Guidelines classify syncope into three major categories [1]:

1. Reflex (Neurally-Mediated) Syncope

Mechanism: Inappropriate reflex causing vasodilation and/or bradycardia leading to transient hypotension

Prodrome typically present: Lightheadedness, warmth, nausea, diaphoresis, visual blurring (10-30 seconds warning)

2. Orthostatic Hypotension (OH)

Definition: SBP decrease ≥20 mmHg or DBP decrease ≥10 mmHg within 3 minutes of standing [3]

Classic presentation: Syncope within seconds to 3 minutes of standing, absent or minimal prodrome

3. Cardiac Syncope

Mechanism: Arrhythmia or structural disease causing critically reduced cardiac output

A. Arrhythmic (most common cardiac cause):

B. Structural Cardiac/Cardiopulmonary:

Typical presentation: Sudden LOC with little/no warning, may occur in any position including supine

---

Epidemiology

Prevalence and Incidence

• Lifetime prevalence: 30-40% of general population will experience at least one syncopal episode [1]
• Emergency department presentations: 1-3% of all ED visits [11]
• Hospital admissions: 1-6% of acute medical admissions [1]
• Recurrence rate:
  • "Vasovagal syncope: 30-40% recurrence over 3 years"
  • "Cardiac syncope: Higher recurrence without definitive treatment"
• Bimodal age distribution: Peak incidence in adolescence (vasovagal) and elderly > 70 years (cardiac, OH) [12]

Etiology Distribution

Based on systematic reviews and guideline data [1,2,13]:

Critical Point: Cardiac syncope carries 20-40% one-year mortality if untreated, compared to less than 5% for non-cardiac causes [14]. This mortality differential mandates aggressive risk stratification.

---

Pathophysiology

Normal Cerebral Perfusion Regulation

Baseline requirements:

• Cerebral blood flow: 50-60 mL/100g brain tissue/min
• Brain requires 15-20% of total cardiac output
• Cerebral autoregulation maintains constant flow across mean arterial pressure (MAP) 60-150 mmHg
• Critical threshold: MAP less than 60 mmHg or cerebral blood flow less than 30 mL/100g/min → loss of consciousness within 6-8 seconds [9]

Mechanisms of Syncope by Type

Reflex (Vasovagal) Syncope

Classic Bezold-Jarisch reflex pathway [15]:

1. Initial orthostatic stress: Prolonged standing → venous pooling in lower extremities
2. Compensatory phase: Baroreceptor activation → ↑ sympathetic tone → ↑ HR, ↑ contractility, vasoconstriction
3. Paradoxical reflex: Vigorous contraction of underfilled LV → activation of mechanoreceptors (C-fibers)
4. Vagal surge: Inappropriate ↑ parasympathetic activity + ↓ sympathetic activity
5. Hemodynamic collapse:
   • Cardioinhibitory (bradycardia, AV block, asystole)
   • Vasodepressor (profound peripheral vasodilation)
   • Mixed (both components) - most common
6. Result: Abrupt ↓ BP and ↓ HR → cerebral hypoperfusion → LOC
7. Recovery: Horizontal position → venous return restored → consciousness returns

Prodromal symptoms (10-30 seconds): Triggered by progressive cerebral hypoperfusion causing nausea, diaphoresis, warmth, visual graying, lightheadedness

Orthostatic Hypotension

Normal orthostatic response: Standing → 500-1000 mL blood pools in lower extremities → baroreceptor reflex → compensatory ↑ HR (10-15 bpm), ↑ SVR, ↑ contractility

Failure mechanisms [3]:

• Autonomic dysfunction: Impaired baroreceptor reflex → inadequate vasoconstriction and HR response
• Volume depletion: Insufficient circulating volume to maintain upright BP
• Venous pooling: Varicose veins, prolonged bed rest, deconditioning
• Drug-induced: Blunted sympathetic response or direct vasodilation

Result: Standing SBP drop ≥20 mmHg or DBP ≥10 mmHg within 3 minutes → cerebral hypoperfusion

Cardiac Syncope - Arrhythmic

Brady-arrhythmias:

• Sinus pause > 3 seconds OR
• Complete heart block with slow ventricular escape
• Result: Cardiac output falls to less than 30% of baseline → immediate cerebral hypoperfusion (no warning prodrome)

Tachy-arrhythmias:

• Ventricular tachycardia (VT) at rates > 150-180 bpm:
  • Shortened diastolic filling time → ↓ stroke volume
  • Loss of atrial contribution → further ↓ cardiac output
  • Especially critical if pre-existing LV dysfunction (LVEF less than 35%)
• Result: Inadequate cardiac output despite tachycardia → syncope

Inherited arrhythmic syndromes [16]:

• Long QT syndrome: Prolonged repolarization → torsades de pointes → VT/VF
• Brugada syndrome: Abnormal Na+ channel function → phase 2 reentry → polymorphic VT
• ARVC: Fibrofatty replacement of RV → ventricular arrhythmias

Cardiac Syncope - Structural

Fixed cardiac output states:

• Aortic stenosis (severe: valve area less than 1.0 cm²): Cannot increase cardiac output with exertion → ↓ cerebral perfusion during exercise
• HOCM: Dynamic LVOT obstruction worsens with ↓ preload (dehydration, standing) or ↑ contractility (exercise) → ↓ forward flow
• Massive PE: Acute RV outflow obstruction → ↓ LV filling → ↓ cardiac output → syncope (often with dyspnea, hypoxia)

---

Clinical Presentation

History: The Cornerstone of Diagnosis

Three critical phases to characterize [1,2]:

1. Pre-Syncope (Before Event)

2. During Syncope

3. Post-Syncope (Recovery Phase)

Key Historical Questions

Essential 10-point inquiry:

1. What were you doing immediately before? (position, activity, triggers)
2. Any warning symptoms? (prodrome nature, duration)
3. Did you have palpitations, chest pain, or difficulty breathing?
4. How long were you unconscious? (witness account critical)
5. Any jerking movements or loss of bladder/bowel control?
6. How did you feel when you woke up? (immediate vs. gradual recovery)
7. Have you had similar episodes before? (pattern, frequency)
8. Any family history of sudden death or fainting? (inherited syndromes)
9. What medications do you take? (especially QT-prolonging, antihypertensives)
10. Do you have any heart problems? (structural disease, prior MI, heart failure)

Physical Examination

Vital Signs - Critical First Assessment

Orthostatic vital signs (mandatory for all patients) [3]:

• Technique:
  • Supine BP/HR after 5 minutes rest
  • Standing BP/HR at 1 and 3 minutes
• Positive if:
  • SBP drop ≥20 mmHg OR DBP drop ≥10 mmHg OR
  • HR increase > 30 bpm (or HR > 120 bpm) = POTS (postural orthostatic tachycardia syndrome)
• Yield: Positive in 12% of unselected syncope patients, 24% of elderly [3]

Current vital signs:

• Hypotension (SBP less than 90): Shock, hemorrhage, cardiac dysfunction
• Severe hypertension (SBP > 180): Risk factor for cardiac syncope [4]
• Bradycardia (less than 40): Sinus node dysfunction, AV block, medications
• Tachycardia (> 100): Arrhythmia, PE, hemorrhage, sepsis
• Hypoxia: PE, cardiac failure

Cardiovascular Examination

Neurological Examination

Purpose: Distinguish syncope from stroke/seizure

Carotid Sinus Massage (CSM)

Indication: Unexplained syncope in elderly (> 60 years), especially with positional triggers [10]

Technique:

• Continuous ECG and BP monitoring
• Supine position, then repeat sitting/standing
• Gentle 5-10 second massage at angle of jaw (carotid bifurcation)
• One side at a time (never bilateral)

Contraindications: Carotid bruit, prior stroke/TIA within 3 months, known carotid stenosis

Positive result:

• Cardioinhibitory: Asystole > 3 seconds
• Vasodepressor: SBP drop > 50 mmHg without significant bradycardia
• Mixed: Both components

Diagnostic yield: 20-30% in selected elderly patients with recurrent unexplained syncope [10]

---

Red Flags and High-Risk Features

Immediate Life-Threatening Concerns

MUST rule out immediately:

1. Acute coronary syndrome: Chest pain + syncope + ECG changes + troponin elevation
2. Massive pulmonary embolism: Dyspnea + hypoxia + syncope + RV strain on ECG
3. Aortic dissection: Severe chest/back pain + pulse deficit + syncope
4. Ruptured AAA: Abdominal/back pain + hypotension + syncope + age > 60
5. Sustained ventricular arrhythmia: Ongoing palpitations + wide-complex tachycardia on monitor
6. Complete heart block: Profound bradycardia (less than 30 bpm) or pauses > 3 seconds
7. Hemorrhage: Anemia + hypotension + syncope (GI bleed, ruptured ectopic, trauma)

High-Risk Clinical Features [1,2,4]

Features mandating admission and intensive investigation:

History

• Syncope during exertion or while supine
• Syncope causing severe injury
• Palpitations at time of syncope
• Family history of SCD at age less than 40 years or inherited cardiac condition
• New or worsening dyspnea or chest pain

Examination

• Persistent hypotension (SBP less than 90 mmHg)
• Severe hypertension (SBP > 180 mmHg) [4]
• Unexplained hypoxia (SpO₂ less than 94%)
• Clinical signs of heart failure
• Cardiac murmur suggesting structural disease
• Severe anemia (Hct less than 30%)

ECG Findings (See Detailed ECG Section)

• Any acute ischemic changes
• Mobitz II or 3rd degree AV block
• Sinus pause > 3 seconds or sinus bradycardia less than 40 bpm (when awake)
• Pre-excitation (WPW pattern)
• Prolonged QT (QTc > 480 ms) or short QT (less than 340 ms)
• Brugada pattern (Type 1)
• Negative T waves in right precordial leads, epsilon waves (ARVC)
• Ventricular hypertrophy with strain
• Bundle branch block with axis deviation (bifascicular block)
• Non-sustained VT or SVT

Comorbidities

• Known structural heart disease (LVEF less than 35%, severe valve disease)
• History of coronary artery disease
• History of arrhythmia
• Age > 60 years (increased cardiac risk)

---

Differential Diagnosis

Distinguishing Syncope from Mimics

Syncope is transient LOC with spontaneous complete recovery. Key differentials:

Syncope Subtypes Differentiation

---

Diagnostic Investigations

Mandatory for ALL Patients

12-Lead ECG

Essential for every syncope patient - Diagnostic yield 5-11% [1,2]

Cardiac Syncope - ECG Findings:

QT Interval Correction (Bazett's formula):

• QTc = QT / √RR interval
• Normal: less than 450 ms (males), less than 460 ms (females)
• Prolonged: > 460 ms (males), > 470 ms (females)
• High risk: > 500 ms (risk of torsades de pointes)

Orthostatic Vital Signs

Method [3]:

1. Patient supine for 5 minutes → measure BP and HR
2. Stand patient (or use tilt table if unable to stand)
3. Measure BP and HR at 1 minute and 3 minutes standing

Diagnostic thresholds:

• Orthostatic hypotension: SBP drop ≥20 mmHg OR DBP drop ≥10 mmHg within 3 min
• Delayed orthostatic hypotension: Drop after 3 minutes (up to 10 minutes)
• POTS: HR increase > 30 bpm (or HR > 120) with less than 20 mmHg SBP drop

Positive in 12% overall, 24% in elderly patients [3]

Point-of-Care Glucose

• Rule out hypoglycemia (especially diabetics, altered mental status)
• Normal: 70-100 mg/dL (3.9-5.6 mmol/L)
• Symptomatic hypoglycemia: typically less than 60 mg/dL (less than 3.3 mmol/L)

Investigations Based on Clinical Suspicion

Advanced Cardiac Investigations

Typically performed during admission or outpatient follow-up for high-risk patients:

Echocardiography

Indications [1,2,7]:

• Exertional syncope (rule out AS, HOCM)
• Cardiac murmur on examination
• Abnormal ECG suggesting structural disease
• Known or suspected heart failure (LVEF assessment)
• Family history of cardiomyopathy

Diagnostic yield: 5-10% in unselected patients; much higher (up to 50%) in selected high-risk patients [7]

Key findings:

• Aortic stenosis: Valve area less than 1.0 cm² (severe), gradient, LVH
• HOCM: Septal hypertrophy (≥15 mm), SAM, LVOT gradient
• LV dysfunction: LVEF less than 35% (high risk for VT, ICD indication)
• Regional wall motion abnormalities: Prior MI, VT substrate
• RV dilation/dysfunction: Acute PE, ARVC, pulmonary hypertension
• Valvular disease: Severity assessment
• Pericardial effusion: Tamponade physiology

Prolonged ECG Monitoring

In-hospital telemetry (24-72 hours):

• High-risk patients admitted for syncope
• Arrhythmia detection rate: 5-15% during hospitalization [17]

Holter monitor (24-48 hours outpatient):

• Low diagnostic yield (1-2%) if symptoms not captured during monitoring period
• Useful only if frequent symptoms (daily)

External loop recorder (14-30 days):

• Patient-activated or auto-triggered
• Higher yield for less frequent symptoms (weekly)
• Diagnostic yield 10-20% [17]

Implantable loop recorder (ILR) (up to 3 years):

• Gold standard for unexplained recurrent syncope [18]
• Indications [1]:
  • Recurrent syncope of unknown cause after full evaluation
  • High-risk features but non-diagnostic workup
  • Suspected arrhythmic syncope but infrequent events
• Diagnostic yield: 50-55% over 12-18 months [18]
• Strategy: Early ILR implantation (before extensive testing) may be cost-effective in selected patients

Tilt Table Testing

Indications [1,19]:

• Recurrent unexplained syncope when reflex syncope suspected but not confirmed
• Differentiate reflex syncope from orthostatic hypotension
• Distinguish syncope from pseudosyncope (psychogenic)
• Evaluate suspected POTS

Contraindications: Severe AS, critical coronary stenosis, severe carotid stenosis

Protocol [19]:

• Supine baseline 5-10 min
• Upright tilt 60-70° for 20-45 minutes (drug-free phase)
• ± Isoproterenol or nitroglycerin provocation if negative (drug phase)

Positive test: Reproduction of syncope or pre-syncope with:

• Vasovagal response: Hypotension ± bradycardia
• POTS: HR ↑ > 30 bpm (or > 120 bpm) within 10 min, symptoms
• Orthostatic hypotension: BP drop without reflex tachycardia

Sensitivity 60-85%, Specificity 90% for reflex syncope [19]

Limitations:

• Low specificity in elderly (high false-positive rate)
• Does not predict recurrence risk
• Normal test does not exclude vasovagal syncope

Electrophysiology Study (EPS)

Indications [1,2]:

• Structural heart disease + unexplained syncope (high risk for VT)
• Bifascicular block with syncope (assess HV interval)
• Suspected SVT (ablation therapy)
• Brugada syndrome, ARVC (risk stratification)
• Pre-excitation (WPW) with syncope

Diagnostic findings:

• HV interval > 70 ms or 2nd/3rd degree block induced: High risk for complete AV block → pacemaker
• Inducible sustained VT/VF: ICD indication
• Inducible SVT: Ablation candidate
• Negative EPS: Does not exclude arrhythmia (consider ILR)

Diagnostic yield: 10-50% depending on patient selection (higher in structural heart disease) [20]

Exercise Stress Testing

Indications:

• Exertional syncope (if AS ruled out by echo)
• Assess for exercise-induced arrhythmia
• Long QT syndrome provocation (QT fails to shorten with exercise)
• Evaluate chronotropic incompetence

Contraindications: Severe AS (exercise testing contraindicated)

Coronary Angiography

Indications:

• Syncope + positive troponin or ischemic ECG changes
• Exertional syncope with cardiovascular risk factors after non-diagnostic echo
• Syncope in patient with known CAD

---

Risk Stratification: Systematic Approach

Goal of Risk Stratification

Identify patients at risk for:

1. Short-term serious outcomes (30 days): Death, life-threatening arrhythmia, structural cardiopulmonary disease, significant hemorrhage
2. Recurrent syncope
3. Need for specific intervention

Canadian Syncope Risk Score (CSRS) - Validated, Recommended [4,5]

Derivation: 4,030 patients across 6 Canadian EDs; Validation: Multiple external cohorts

Scoring (range: -3 to +11):

Risk stratification (30-day serious outcome):

• Very Low Risk (Score -2 to 0): 0.4% → Safe for discharge
• Low Risk (Score 1-3): 3.6% → Consider short-stay unit or close outpatient follow-up
• Medium Risk (Score 4-5): 12.9% → Admit for investigation
• High Risk (Score ≥6): 28.9% → Admit for intensive investigation

Recommendation: Score ≥1 → consider admission or intensive outpatient investigation [4]

San Francisco Syncope Rule (SFSR) [6]

Mnemonic: CHESS Admit if ANY of the following present:

• C: CHF history
• H: Hematocrit less than 30%
• E: ECG abnormality (any non-sinus rhythm, new changes, or concerning finding)
• S: Shortness of breath
• S: Systolic BP less than 90 mmHg at triage

Performance [6]:

• Sensitivity: 98% (very few missed serious outcomes)
• Specificity: 56% (many low-risk patients flagged)
• NPV: 99.7% (very safe to discharge if all criteria absent)

Limitation: "Abnormal ECG" is broadly defined; many low-risk patients have ECG abnormalities

OESIL Score (Osservatorio Epidemiologico sulla Sincope nel Lazio)

Risk (1-year mortality):

• Score 0: 0%
• Score 1: 0.8%
• Score 2: 19.6%
• Score 3: 34.7%
• Score 4: 57.1%

Less commonly used in North American practice; CSRS preferred

ESC 2018 Risk Stratification [1]

High risk features warranting immediate evaluation:

• Severe structural or coronary disease (HF, LVEF less than 35%, previous MI)
• Clinical or ECG features suggesting arrhythmic syncope:
  • Syncope during exertion or supine
  • Palpitations at time of syncope
  • Family history of SCD
  • Non-sustained VT
  • Bifascicular block or other conduction abnormalities
  • Sinus bradycardia less than 50 bpm or sino-atrial block (when awake, not athletes)
  • Pre-excitation (WPW)
  • Long or short QT
  • Brugada pattern
  • Negative T waves in right precordial leads (ARVC)
• Syncope causing severe injury
• Comorbidities: anemia, electrolyte disturbance

Intermediate risk (short-stay ED observation unit acceptable):

• Age > 60 years without high-risk features
• No prodromal symptoms
• Unclear etiology after initial evaluation

Low risk (discharge appropriate):

• Clear vasovagal or situational trigger
• Typical prodrome
• No high-risk features
• Normal ECG, normal vital signs including orthostatic

---

Management and Treatment

General Principles

1. Stabilize: Address acute life-threatening causes (arrhythmia, MI, PE, hemorrhage)
2. Risk stratify: Use validated tools (CSRS, SFSR) to determine disposition
3. Diagnose etiology: History, examination, ECG, orthostatic vitals
4. Treat underlying cause: Specific interventions based on etiology
5. Prevent recurrence: Modify risk factors, patient education

Emergency Management by Etiology

Vasovagal Syncope (Low Risk)

Acute treatment:

• Reassurance (benign condition)
• Supine positioning until symptoms resolve
• Oral fluids if tolerated

Long-term prevention [1,15]:

• Education: Most important intervention
  • Recognize prodromal symptoms → lie down immediately
  • Avoid triggers (prolonged standing, dehydration, heat, alcohol, large meals)
• Hydration: 2-3 L fluid daily
• Salt supplementation: 6-10 g/day (contraindicated in hypertension, heart failure)
• Physical counterpressure maneuvers:
  • Leg crossing with tensing
  • Squatting
  • Arm tensing (handgrip)
  • "Effectiveness: 40% reduction in recurrence [21]"
• Tilt training: Controversial, limited evidence
• Pharmacotherapy (reserved for refractory cases):
  • "Midodrine (α-agonist): 5-10 mg TID, modest benefit [22]"
  • "Fludrocortisone: 0.1-0.3 mg daily, weak evidence"
  • "β-blockers: NOT effective (may worsen) [23]"
  • "SSRIs: Inconsistent evidence"

Pacing: Generally NOT indicated for vasovagal syncope (exception: severe cardioinhibitory type with recurrent injury despite conservative measures) [1]

Prognosis: Excellent (benign condition, recurrence does not affect mortality)

Orthostatic Hypotension

Acute treatment:

• IV fluid resuscitation if volume depleted
• Supine/Trendelenburg positioning

Long-term management [3]:

1. Identify and treat underlying cause:

   • Medication review: Reduce/discontinue offending agents (diuretics, α-blockers, antihypertensives, nitrates, tricyclics)
   • Volume depletion: Treat dehydration, hemorrhage, adrenal insufficiency
   • Autonomic dysfunction: Treat underlying condition (optimize Parkinson's medications, diabetic control)

2. Non-pharmacologic measures (first-line):

   • Volume expansion: 2-3 L fluid daily, salt intake 6-10 g/day
   • Compression stockings: Waist-high 30-40 mmHg
   • Physical countermaneuvers: Leg crossing, squatting before standing
   • Elevate head of bed: 10-20° (reduces nocturnal diuresis)
   • Small frequent meals: Avoid post-prandial hypotension
   • Gradual position changes: Sit at edge of bed before standing
   • Avoid heat, alcohol, large meals

3. Pharmacologic treatment (if non-pharm insufficient):

   • Midodrine (α₁-agonist): 2.5-10 mg TID, take before upright activities [24]
     • Contraindications: Supine hypertension, urinary retention, hyperthyroidism
   • Fludrocortisone (mineralocorticoid): 0.1-0.3 mg daily
     • Contraindications: Heart failure, hypertension, hypokalemia
   • Droxidopa (norepinephrine precursor): 100-600 mg TID for neurogenic OH
   • Pyridostigmine (acetylcholinesterase inhibitor): 30-60 mg TID

Prognosis: Depends on underlying etiology; significant fall/injury risk in elderly

Cardiac Syncope - Arrhythmic

A. Bradyarrhythmias:

Pacing indications (Class I - indicated) [25]:

• Symptomatic sinus node dysfunction
• 2nd degree Mobitz II or 3rd degree AV block (symptomatic or asymptomatic)
• Bifascicular block with syncope if HV interval > 70 ms or block induced at EPS

B. Tachyarrhythmias:

ICD indications (syncope context) [26]:

• Secondary prevention: Survived VT/VF arrest (Class I)
• Primary prevention:
  • LVEF ≤35% + NYHA II-III + syncope concerning for VT (Class I)
  • HOCM with syncope + risk factors (family history SCD, NSVT, massive LVH) (Class IIa)
  • ARVC with syncope + inducible VT or high-risk features (Class IIa)
  • Long QT syndrome with syncope despite β-blockers (Class IIa-IIb)
  • Brugada syndrome with syncope (Class IIa)

C. Inherited Arrhythmic Syndromes:

Cardiac Syncope - Structural

Aortic stenosis: Syncope is a Class I indication for AVR (symptomatic severe AS = very high mortality without intervention, 50% 2-year mortality) [30]

HOCM: Syncope indicates high-risk features; consider ICD for primary prevention if additional risk factors present [31]

Hemorrhage

• Immediate: 2 large-bore IVs, aggressive resuscitation, type and cross, transfuse if Hb less than 7 g/dL (or less than 8 in CAD)
• GI bleed: PPI, GI consult, endoscopy
• Ruptured ectopic: Emergent gynecology consult, surgical management
• Ruptured AAA: Vascular surgery, emergent repair

---

Disposition and Follow-Up

Admission Criteria

Mandatory admission:

• CSRS ≥4 (medium/high risk)
• Any life-threatening diagnosis (MI, PE, dissection, severe arrhythmia, hemorrhage)
• Unexplained syncope with any high-risk feature [1]:
  • Severe structural or coronary disease
  • Clinical or ECG features suggesting arrhythmic syncope
  • Syncope during exertion or causing severe injury
  • Comorbidities (severe anemia, electrolyte abnormalities)

Consider admission or observation unit (6-24 hours):

• CSRS 1-3 (low risk) with uncertain diagnosis
• Age > 60 years without clear etiology
• Need for brief observation and additional testing (echo, prolonged monitoring)

Safe Discharge Criteria

All of the following must be met:

1. Clear vasovagal or situational diagnosis with typical features
2. No high-risk features:
   • No exertional or supine syncope
   • No cardiac symptoms (chest pain, dyspnea, palpitations)
   • No family history of SCD
   • No known structural heart disease
3. Normal investigations:
   • Normal or non-concerning ECG
   • Normal orthostatic vital signs (or diagnosed OH with addressed cause)
   • Normal vital signs
4. CSRS ≤0 (very low risk)
5. Reliable follow-up arranged

Discharge Instructions for Low-Risk Vasovagal Syncope

Patient education (critical for recurrence prevention):

• "You had a fainting spell caused by a temporary drop in blood pressure. This is a benign reflex that does not indicate heart or brain problems."
• Warning signs: "If you feel faint coming on (lightheaded, warm, nauseous, vision dimming), immediately lie down flat or sit with head between knees."
• Hydration: "Drink 8-10 glasses of water daily."
• Avoid triggers: "Avoid prolonged standing, hot environments, dehydration, alcohol, skipping meals."
• Gradual position changes: "Stand up slowly from sitting/lying."
• Counterpressure maneuvers: Teach leg crossing with tensing, squatting

Return precautions:

• Recurrent syncope (especially if different pattern)
• Syncope during exertion or lying down
• Chest pain, severe shortness of breath
• Palpitations
• Severe headache or neurological symptoms
• Syncope causing injury

Follow-Up Arrangements

---

Special Populations

Elderly (Age > 65 Years)

Unique considerations [12]:

• Higher prevalence of cardiac causes: 30-40% vs. 10-20% in younger patients
• Multifactorial etiology: Often > 1 contributing cause (polypharmacy, dehydration, OH, arrhythmia)
• Higher injury risk: 30-40% sustain injury from syncope-related falls (fractures, head trauma)
• Atypical presentations: May lack classic prodrome
• Orthostatic hypotension: Present in 24% [3]
• Carotid sinus hypersensitivity: 20-30% prevalence in unexplained syncope [10]

Management approach:

• Lower threshold for admission (age > 60 is CSRS +0 but higher cardiac risk)
• Comprehensive medication review: Polypharmacy major contributor
• Assess for carotid sinus hypersensitivity: Consider CSM in appropriate patients
• Evaluate for multi-factorial causes: Address all contributors
• Fall risk assessment: Physical therapy, home safety evaluation
• Driving restrictions: Consider state-specific regulations

Athletes

Exertional syncope in athletes is high-risk [32]:

Differential diagnosis:

• HOCM: Most common cause of SCD in young athletes
• ARVC: Right ventricular cardiomyopathy
• Anomalous coronary artery: Coronary artery arising from wrong sinus
• Long QT syndrome, Brugada syndrome: Channelopathies
• Myocarditis: Acute viral illness
• Commotio cordis: Blunt chest trauma during vulnerable phase

Work-up:

• Detailed history: Timing (during vs. after exercise), prodrome, family history SCD
• 12-lead ECG: Distinguish physiologic athlete's heart from pathologic findings
• Echocardiography: Assess for HOCM (septal thickness), other structural disease
• Exercise stress test: Provoke arrhythmia, assess QT response
• Cardiac MRI: If ARVC suspected
• Genetic testing: If inherited syndrome suspected

Management:

• Restrict competitive sports until diagnosis established
• Cardiology referral mandatory for all athletes with exertional syncope
• Screening family members if inherited condition identified

Pregnancy

Physiologic changes predisposing to syncope:

• ↑ Blood volume (30-50%) but ↓ SVR → orthostatic intolerance
• Compression of IVC by gravid uterus (supine hypotensive syndrome)
• Vasovagal syncope common in pregnancy

High-risk causes to exclude:

• Ruptured ectopic pregnancy: 1st trimester syncope + abdominal pain
• Pulmonary embolism: Pregnancy is hypercoagulable state (5-10× ↑ risk)
• Peripartum cardiomyopathy: Late pregnancy/early postpartum
• Amniotic fluid embolism: Rare, catastrophic (during labor/delivery)

Investigations:

• β-hCG (confirm pregnancy, quantify for ectopic risk)
• ECG (avoid radiation but PE must be ruled out if suspected)
• Ultrasound (transvaginal for ectopic, pelvic for free fluid)
• D-dimer less useful (physiologically elevated in pregnancy)

Management:

• Avoid supine position after 20 weeks (left lateral decubitus)
• Hydration, compression stockings
• Low threshold for PE workup (CTPA or V/Q scan acceptable; fetal radiation dose low)

Drivers (Occupational Risk)

Driving restrictions vary by jurisdiction:

General principles [1]:

• High-risk cardiac syncope: Restrict driving until treated and arrhythmia-free
  • "ICD implantation: 3-6 month restriction"
  • "Unexplained syncope with high-risk features: Restrict until diagnosis established"
• Low-risk vasovagal: May resume driving once educated on prodrome recognition
• Commercial drivers: Stricter regulations, typically require clearance from cardiologist

Physician responsibility: Inform patients of driving risks; mandatory reporting laws vary by state/country

---

Prognosis and Outcomes

Mortality Risk by Etiology

Key point: Cardiac syncope has 20-40× higher mortality than vasovagal syncope [14]

Recurrence Risk

• Vasovagal: 30-40% recurrence over 3 years [15]
• Cardiac (untreated): Frequent recurrence until arrhythmia/structural disease treated
• Orthostatic: Recurrent if underlying cause not addressed
• Unexplained: Variable; consider ILR if recurrent (diagnostic yield 50-55% over 18 months) [18]

Injury Risk

• Overall injury rate: 30-40% of syncope episodes result in injury
• Elderly: Higher risk of fractures (hip, wrist), head trauma, prolonged hospitalization
• Exertional syncope: Risk of injury during activity (driving, swimming, athletics)
• Sudden onset (no prodrome): Higher injury risk (no protective response)

Quality of Life Impact

• Recurrent syncope significantly impairs QOL (comparable to chronic conditions like rheumatoid arthritis)
• Anxiety, fear of recurrence, activity restriction
• Employment impact (inability to drive, work restrictions)
• Importance of definitive diagnosis and treatment to improve QOL

---

Key Clinical Pearls

Diagnostic Pearls

1. Sudden LOC without warning = arrhythmia until proven otherwise (high risk)
2. Exertional syncope = structural heart disease or arrhythmia (always investigate: echo + stress test)
3. Supine syncope = arrhythmia (no orthostatic component; very concerning)
4. Vasovagal syncope is a diagnosis of EXCLUSION (must rule out cardiac causes first with ECG, orthostatic vitals)
5. ECG is essential in every patient (diagnostic yield 5-11%, may identify life-threatening condition) [1,2]
6. Orthostatic vital signs are mandatory (positive in 12-24%, simple bedside test) [3]
7. Age > 60 years = higher threshold for admission (increased cardiac risk, injury risk)
8. Syncope with chest pain = ACS or PE until proven otherwise (troponin, ECG, consider D-dimer/CTPA)
9. Family history of SCD less than 40 years = inherited syndrome (long QT, Brugada, ARVC, HOCM)
10. Bifascicular block + syncope = high risk for complete heart block (EP study, consider pacing)

Risk Stratification Pearls

1. Use Canadian Syncope Risk Score (validated, objective, excellent discrimination) [4,5]
2. CSRS ≥1 = consider admission or intensive investigation (3.6% serious outcome risk)
3. CSRS ≤0 + normal ECG + vasovagal features = safe discharge (0.4% risk)
4. San Francisco Syncope Rule is highly sensitive (98%) but not specific (56%) - useful to rule OUT high risk [6]
5. Multiple risk scores positive = admit (high risk of adverse outcome)

Management Pearls

1. Low-risk vasovagal = reassurance + education (most effective intervention, prevent recurrence with prodrome recognition)
2. Treat dehydration aggressively (IV fluids for orthostatic, volume depletion)
3. Review medications in every patient (polypharmacy major cause of orthostatic syncope)
4. Cardiac syncope requires admission and monitoring (arrhythmia detection, definitive treatment)
5. Symptomatic severe AS = urgent AVR (Class I indication, 50% 2-year mortality without surgery) [30]
6. β-blockers do NOT prevent vasovagal syncope (may worsen; avoid) [23]
7. Physical counterpressure maneuvers are effective (leg crossing, squatting; 40% ↓ recurrence) [21]
8. Implantable loop recorder for unexplained recurrent syncope (50-55% diagnostic yield, cost-effective) [18]
9. ICD for syncope + LVEF less than 35% (primary prevention of SCD) [26]
10. Permanent pacemaker for syncope + bifascicular block if HV > 70 ms (prevent complete heart block) [25]

Disposition Pearls

1. High-risk features = admit for telemetry and investigation (cardiac causes have 20-40% 1-year mortality) [14]
2. Low-risk with clear vasovagal diagnosis = safe discharge with education
3. Elderly: lower threshold to admit (higher cardiac risk, injury risk, multifactorial)
4. Unexplained syncope with high-risk features = cardiology referral + consider ILR [18]
5. Athletes with exertional syncope = restrict sports, urgent cardiology referral [32]
6. Driving restrictions: High-risk cardiac until treated; low-risk after prodrome education

---

Quality Metrics and Documentation

Performance Indicators

Essential Documentation Elements

History:

• Position at onset (standing, sitting, supine, exertion)
• Triggers (if present)
• Prodromal symptoms (nature, duration)
• Witness account (duration of LOC, motor activity, color change)
• Recovery (immediate vs. gradual, confusion, injury)
• Prior episodes
• Family history of SCD or syncope
• Medications (including recent changes)
• Cardiac history (structural disease, arrhythmia, prior MI)

Examination:

• Complete vital signs including orthostatic BP/HR (supine and standing at 1 and 3 min)
• Cardiovascular examination (rhythm, murmurs, JVP)
• Neurological examination (document normal if no deficits)

Investigations:

• ECG interpretation (rhythm, intervals, concerning features)
• Labs (if obtained)

Risk stratification:

• Canadian Syncope Risk Score (calculate and document)
• High-risk features present or absent

Disposition rationale:

• Clear justification for admission or discharge based on risk assessment
• Follow-up plan (specialty, timeframe)
• Discharge instructions documented (if discharged)

---

References

1. Brignole M, Moya A, de Lange FJ, et al. 2018 ESC Guidelines for the diagnosis and management of syncope. Eur Heart J. 2018;39(21):1883-1948. doi:10.1093/eurheartj/ehy037

2. Shen WK, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2017;70(5):e39-e110. doi:10.1016/j.jacc.2017.03.003

3. Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21(2):69-72. doi:10.1007/s10286-011-0119-5

4. Thiruganasambandamoorthy V, Kwong K, Wells GA, et al. Development of the Canadian Syncope Risk Score to predict serious adverse events after emergency department assessment of syncope. CMAJ. 2016;188(12):E289-E298. doi:10.1503/cmaj.151469

5. Thiruganasambandamoorthy V, Stiell IG, Sivilotti MLA, et al. Predicting Short-term Risk of Arrhythmia Among Patients With Syncope: The Canadian Syncope Arrhythmia Risk Score. Acad Emerg Med. 2017;24(11):1315-1326. doi:10.1111/acem.13275

6. Quinn JV, Stiell IG, McDermott DA, et al. Derivation of the San Francisco Syncope Rule to predict patients with short-term serious outcomes. Ann Emerg Med. 2004;43(2):224-232. doi:10.1016/S0196-0644(03)00823-0

7. Mendu ML, McAvay G, Lampert R, et al. Yield of diagnostic tests in evaluating syncopal episodes in older patients. Arch Intern Med. 2009;169(14):1299-1305. doi:10.1001/archinternmed.2009.204

8. Costantino G, Perego F, Dipaola F, et al. Short- and long-term prognosis of syncope, risk factors, and role of hospital admission: results from the STePS (Short-Term Prognosis of Syncope) study. J Am Coll Cardiol. 2008;51(3):276-283. doi:10.1016/j.jacc.2007.08.059

9. van Lieshout JJ, Wieling W, Karemaker JM, et al. Syncope, cerebral perfusion, and oxygenation. J Appl Physiol. 2003;94(3):833-848. doi:10.1152/japplphysiol.00260.2002

10. Parry SW, Reeve P, Lawson J, et al. The Newcastle protocols 2008: an update on head-up tilt table testing and the management of vasovagal syncope and related disorders. Heart. 2009;95(5):416-420. doi:10.1136/hrt.2007.136457

11. Sun BC, Emond JA, Camargo CA Jr. Characteristics and admission patterns of patients presenting with syncope to U.S. emergency departments, 1992-2000. Acad Emerg Med. 2004;11(10):1029-1034. doi:10.1197/j.aem.2004.05.032

12. Soteriades ES, Evans JC, Larson MG, et al. Incidence and prognosis of syncope. N Engl J Med. 2002;347(12):878-885. doi:10.1056/NEJMoa012407

13. Gauer RL. Evaluation of syncope. Am Fam Physician. 2011;84(6):640-650.

14. Kapoor WN. Syncope. N Engl J Med. 2000;343(25):1856-1862. doi:10.1056/NEJM200012213432507

15. Mosqueda-Garcia R, Furlan R, Tank J, et al. The elusive pathophysiology of neurally mediated syncope. Circulation. 2000;102(23):2898-2906. doi:10.1161/01.cir.102.23.2898

16. Schwartz PJ, Ackerman MJ, Antzelevitch C, et al. Inherited cardiac arrhythmias. Nat Rev Dis Primers. 2020;6(1):58. doi:10.1038/s41572-020-0188-7

17. Schladenhaufen R, Feilhauer K, Mortl D, et al. ECG Monitoring for detection of arrhythmias in patients with syncope. Herzschrittmacherther Elektrophysiol. 2022;33(1):32-38. doi:10.1007/s00399-021-00829-9

18. Brignole M, Vardas P, Hoffman E, et al. Indications for the use of diagnostic implantable and external ECG loop recorders. Europace. 2009;11(5):671-687. doi:10.1093/europace/eup097

19. Deharo JC, Guieu R, Mechulan A, et al. Syncope without prodromes in patients with normal heart and normal electrocardiogram: a distinct entity. J Am Coll Cardiol. 2013;62(12):1075-1080. doi:10.1016/j.jacc.2013.05.060

20. Zimetbaum PJ, Josephson ME. The evolving role of ambulatory arrhythmia monitoring in general clinical practice. Ann Intern Med. 1999;130(10):848-856. doi:10.7326/0003-4819-130-10-199905180-00016

21. van Dijk N, Quartieri F, Blanc JJ, et al. Effectiveness of physical counterpressure maneuvers in preventing vasovagal syncope: the Physical Counterpressure Maneuvers Trial (PC-Trial). J Am Coll Cardiol. 2006;48(8):1652-1657. doi:10.1016/j.jacc.2006.06.059

22. Perez-Lugones A, Schweikert R, Pavia S, et al. Usefulness of midodrine in patients with severely symptomatic neurocardiogenic syncope: a randomized control study. J Cardiovasc Electrophysiol. 2001;12(8):935-938. doi:10.1046/j.1540-8167.2001.00935.x

23. Sheldon R, Connolly S, Rose S, et al. Prevention of Syncope Trial (POST): a randomized, placebo-controlled study of metoprolol in the prevention of vasovagal syncope. Circulation. 2006;113(9):1164-1170. doi:10.1161/CIRCULATIONAHA.105.535161

24. Low PA, Gilden JL, Freeman R, et al. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. JAMA. 1997;277(13):1046-1051.

25. Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay. J Am Coll Cardiol. 2019;74(7):e51-e156. doi:10.1016/j.jacc.2018.10.044

26. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. J Am Coll Cardiol. 2018;72(14):e91-e220. doi:10.1016/j.jacc.2017.10.054

27. Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia. J Am Coll Cardiol. 2016;67(13):e27-e115. doi:10.1016/j.jacc.2015.08.856

28. Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Heart Rhythm. 2013;10(12):1932-1963. doi:10.1016/j.hrthm.2013.05.014

29. Antzelevitch C, Yan GX, Ackerman MJ, et al. J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge. Heart Rhythm. 2016;13(10):e295-e324. doi:10.1016/j.hrthm.2016.07.019

30. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. J Am Coll Cardiol. 2021;77(4):e25-e197. doi:10.1016/j.jacc.2020.11.018

31. Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2020;76(25):e159-e240. doi:10.1016/j.jacc.2020.08.045

32. Maron BJ, Zipes DP, Kovacs RJ. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Preamble, Principles, and General Considerations. J Am Coll Cardiol. 2015;66(21):2343-2349. doi:10.1016/j.jacc.2015.09.032